Heart muscle blood flow changes after optimal treatment in obstructive hypertrophic cardiomyopathy
Myocardial Perfusion Changes Following Optimal Medical Treatment in Symptomatic Hypertrophic Cardiomyopathy
This study will test whether changes in walking distance over six minutes match changes in heart muscle blood flow in adults with obstructive hypertrophic cardiomyopathy on optimal medical therapy.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 20 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Medical University of Vienna Academic / other |
| Locations | 1 site (Vienna) |
| Trial ID | NCT07150299 on ClinicalTrials.gov |
What this trial studies
This is a single-center observational study enrolling adults with obstructive hypertrophic cardiomyopathy who have clinically indicated cardiac magnetic resonance (CMR) perfusion scans. Participants undergo baseline and follow-up CMR perfusion imaging to measure myocardial perfusion reserve (MPR) while receiving guideline-conform optimal medical therapy, which in routine care may include mavacamten. Functional capacity is measured with the six-minute walk test (6MWT) at the same time points and changes in 6MWT distance will be correlated with changes in MPR. The study excludes patients with significant coronary disease, severe renal or hepatic impairment, or contraindications to CMR.
Who should consider this trial
Good fit: Adults over 18 with obstructive HCM per ESC 2023 criteria who are on guideline-conform optimal medical therapy, scheduled for or having had clinical CMR perfusion imaging, and able to complete follow-up visits and a 6MWT are ideal candidates.
Not a fit: Patients with significant coronary artery disease, alternative causes of hypertrophy (like amyloidosis or Fabry), severe renal or hepatic impairment, contraindications to CMR, or pregnancy are unlikely to benefit from this study's findings.
Why it matters
Potential benefit: If successful, this could help doctors use a simple walk test alongside CMR to see whether treatments are improving blood flow to the heart muscle and guide management.
How similar studies have performed: Previous work has documented microvascular dysfunction in HOCM and the ability of CMR perfusion to detect it, but direct links between changes in MPR and 6MWT during routine optimal medical therapy are limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age \> 18 years * Willingness to provide written informed consent * Diagnosis of obstructive HCM based on ESC 2023 criteria * Planned CMR with myccardial perfusion for clinical purposes * Receiving guideline-conform OMT * Ability and willingness to undergo follow-up imaging and testing * Written informed consent Exclusion Criteria: * Claustrophobia or other contraindication for CMR imaging * Significant coronary artery disease and/or prior stent implantation or coronary artery bypass graft surgery * History of sudden cardiac arrest or sustained ventricular arrhythmia 12 months prior to screening * Glomerular filtration rate \< 30ml/min/m2 * Significant hepatic impairment defined as 3x upper limit of normal of transaminases, total bilirubin, or alkaline phosphatase; hepatic cirrhosis * Known allergy to contrast agent * Alternative disease causing hypertrophic cardiomyopathy (e.g. cardiac amyloidosis, Morbus Fabry) * Pregnant women (and women with childbearing potential with desire for pregnancy) * Breastfeeding women * Unwillingness to comply with the study protocol and its procedures
Where this trial is running
Vienna
- Medical University of Vienna — Vienna, Austria (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.